minimum base quality of q25, minimum base depth of 25, strand bias threshold, and allele frequency of ≥1% with the exception of AR which had an allele frequency threshold of ≥0.5% as validated previously 3 . In addition to the above filters, false positive variant calls arising due to the given sequencing run were assessed, tracked, and filtered out using 11 negative controls sequenced in this study. Variant calls that were coding silent or that were designated as common in populations by dbSNP 8 , EXaC 9 , TCGA 10 , and ClinVar 11 reference databases were excluded from analyses. ClinVar was used to determine pathogenicity of missense mutations 11 . Missense mutations that were pathogenic or likely pathogenic by ClinVar were used for analyses. Highconfidence somatic variants were further annotated with information from COSMIC 12 , Mutation
Assessor, and cBioPortal 13 . Final variant calls were visualized and assessed further for validity using Integrated Genome Viewer (IGV) 14 . For patients with allelic fractions of ClinVar pathogenic or likely pathogenic BRCA1 or BRCA2 mutations that were ≥20%, germline information was obtained through clinical records or by sequencing germline leukocyte DNA obtained from isolated buffy coat. Finally, samples with low input for NGS, the lack of genetic alteration detection was considered indeterminate as opposed to negative.
CN Variation
NGS-based CN detection was performed using an in-house developed algorithm, TMM-CNV and third-party tool, CNVKit 15 . TMM-CNV calculates trimmed mean and corresponding two standard deviations from mean relative coverage depths obtained for the sample and a mean of multiple references including sequence of 9 healthy controls (pool of controls). Data distribution at the gene level was used to apply a trimmed mean of 0.2, 0.1 and corresponding standard deviation to calculate and set the lower and upper thresholds for calling focal deletions and focal amplifications respectively. For autosomes a log2 value of mean relative coverage depth between sample and pool of controls was used, whereas for chromosome X, a logarithmic value of mean relative coverage depth between sample and pool of controls was used. Final copy number calls between TMM-CNV and CNVKit were compared for consensus. Final copy number calls were visualized and assessed further for validity using the in-house MDLVC. Conservative thresholds based on heterozygous SNP fractions of control cfDNA were used to call CN gain and deletion.
Given that it is targeted, gene panel sequencing and tumor cellularity varies in cfDNA sequencing, two thresholds were applied to detect copy gains and losses. CN gain for autosomes was defined by a log2 ratio of mean relative sequencing coverage at the gene level ≥ 0.4 and ≥ 1.2. CN loss for autosomes was defined by a log2 ratio of mean relative sequencing coverage at the gene level ≤ -0.4 and ≤ -1.0. For chromosome X, CN gain was defined by a logarithmic ratio of mean relative sequencing coverage at the gene level ≥ 0.7 and ≥ 1.2 and CN loss was defined by a logarithmic ratio of mean relative sequencing coverage at the gene level ≤ -0.4 and ≤ -1.0.
Estimation of ctDNA Fraction
Estimation of high verse low ctDNA fraction was based upon both mutant allele fraction (MAF) and CN alterations. The fraction of ctDNA (% ctDNA) was estimated based upon the highest autosomal variant allele fraction. ctDNA burden was dichotomized into high and low for statistical analyses. Patients with low ctDNA burden had a ClinVar-annotated pathogenic or likely pathogenic missense mutation or truncating mutation MAF < 7%. Conversely, patients with a high ctDNA burden had a ClinVar-annotated pathogenic or likely pathogenic missense mutation or truncating mutation MAF ≥ 7% and/or a CN loss ≤ -0.55 and/or a CN gain ≥ 1.0.
Statistical Analyses
Sample size estimate of 60 informative patients was calculated prior to study initiation. Power and confidence bounds were calculated using PASS 11 (NCSS Software). Chi-squared tests and logistic regression were used to determine associations between genomic status and PSA response. Kaplan-Meier methods and log-rank tests were used to estimate survival functions.
Cox proportional-hazard modeling was used to estimate PFS and OS. Due to small sample size, clinical variables were dichotomized. PSA was dichotomized at 20ng/mL based on the median PSA of 19.3ng/mL. Age was dichotomized at 72 years based on the median age of 71.5 years.
Prior abiteraterone and enzalutamide was dichotomized as yes or no, visceral metastasis was dichotomized as yes or no, and ctDNA burden was dichotomized as low or high. Multivariable models included only two variables to reduce the likelihood of overfitting. Statistical analyses were performed using STATA SE/15.1, and GraphPad Prism 5 was used for figure generation. 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 -100 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 -100 Supplemental Figure S4 
